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Available online 7 December 2012Abstract Alzheimer's disease (AD) is a neurodegenerative disorder that causes progressive memory and cognitive decline due
to the selective neuronal loss in the cortex and hippocampus of the brains. Generation of human induced pluoripotent stem
(hiPS) cells holds great promise for disease modeling and drug discovery in AD. In this study, we used neurons with forebrain
marker expression from two unrelated hiPS cell lines. As both populations of neurons were vulnerable to β-amyloid 1–42
(Aβ1–42) aggregates, a hallmark of AD pathology, we used them to investigate cellular mediators of Aβ1–42 toxicity. We
observed in neurons differentiated from both hiPS cell lines that Aβ induced toxicity correlated with cell cycle re-entry and
was inhibited by pharmacological inhibitors or shRNAs against Cyclin-dependent kinase 2 (Cdk2). As one of the hiPS cell lines
has been developed commercially to supply large quantities of differentiated neurons (iCell® Neurons), we screened a
chemical library containing several hundred compounds and discovered several small molecules as effective blockers against
Aβ1–42 toxicity, including a Cdk2 inhibitor. To our knowledge, this is the first demonstration of an Aβ toxicity screen using
hiPS cell-derived neurons. This study provided an excellent example of how hiPS cells can be used for disease modeling and
high-throughput compound screening for neurodegenerative diseases.
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Induced pluripotent stem (iPS) cells are a type of pluripotent
stem cells by forced expression of reprogramming transcrip-
tion factors (Takahashi and Yamanaka, 2006; Yu et al., 2007).
Similar to human embryonic stem (ES) cells, human iPS (hiPS)
cells can be differentiated into derivatives of the three
primary germ layers, such as cardiomyocytes of mesoderm
(Wei et al., 2012), pancreatic cells of endoderm (Zhang et al.,
2009) and neurons of ectoderm (Bardy et al., 2012; Petit et
al., 2011). This breakthrough holds great promise for its
applications in cell transplantation, human disease modeling
and drug discovery (Laustriat et al., 2010). Despite many
attempts to use hiPS cells to model human neurodegenerative
diseases for the last five years since they have been available
(Brennand et al., 2010; Dimos et al., 2008; Ebert et al., 2009;
Israel et al., 2012; Lee et al., 2009; Shi et al., 2012; Song
et al., 2011), there are still many challenges. For some
neurodegenerative diseases with long latency periods such as
Alzheimer's disease (AD) and Parkinson disease (PD), it is
unclear whether the late-onset disease phenotypes could be
recapitulated in iPS cellular models.
AD is one of themost common neurodegenerative disorders
in aged individuals. It is characterized by neuropathological
hallmarks including amyloid plaques, neurofibrillary tangles
(NFTs) and eventually neuronal loss in the cerebral cortex and
hippocampus. β-amyloid (Aβ) is a peptide of 36–43 amino
acids which is processed by successive action of the β and γ
secretases from the amyloid precursor protein (APP) and it is
most commonly known to be associated with AD (Vassar,
2005). Since β-amyloid 1–42 (Aβ1–42) is one of the main
components of the amyloid plaques, it is thought that the
accumulation of Aβ1–42 in the brain correlates with AD
severity significantly (Cummings and Cotman, 1995). However,
the recent failure of clinical studies with γ-secretase
inhibitor (semagacestat) (Schor, 2011) has raised questions
about whether the clearance of Aβ plaques would treat AD
effectively. Therefore, in our study we focused on the
investigation of key intracellular mediators of Aβ toxicity
through screens of chemical inhibitors against Aβ1–42 toxic
effects on hiPS cell-derived neurons.
Among the many cellular pathways contributing to cell
death, cell cycle dysregulation is thought to be particu-
larly relevant to neurons. Attempts to re-enter cell cycle
induced by insults would conflict with their terminally
differentiated, non-dividing state (Copani et al., 2001;
Greene et al., 2007; Yang et al., 2003). In proliferating
cells, cell cycle is precisely regulated by the interactions
between Cyclin-dependent kinases (Cdks) and their obli-
gate Cyclin partners. The Cdks are activated via binding
with their corresponding Cyclins, and then these activated
complexes phosphorylate downstream substrates to initi-
ate a series of cellular events such as DNA replication,
chromosome separation and cell division. Tumor suppres-
sor retinoblastoma protein (Rb) is one substrate of the
Cdk4/6 and Cdk2. Unphosphorylated Rb plays a role in
sequestering transcription factors required for S phase
entry. Once the Rb is phosphorylated by the Cdks, the
phosphorylated Rb (phos-Rb) reduces its affinity for the
transcription factor E2F1. E2F1 is then released from the
inhibitory complex E2F-DP and directs the transcription of
the S phase specific genes (Nevins, 1992). In post-mitoticcells such as neurons, the cells are held in G0 phase and
they withdraw from the cell cycle by lack of active Cdk–
Cyclin complexes for cell cycle progression.
In some neurodegenerative diseases such as AD, PD and
amyotrophic lateral sclerosis, ectopic cell cycle events (CCEs)
have been observed in post-mitotic neurons (Bonda et al.,
2009; Lim and Qi, 2003; Ranganathan and Bowser, 2003; Smith
et al., 2004). In the 1990s, several groups reported that cell
cycle markers were expressed in the brains of AD patients
(Baumann et al., 1993; Vincent et al., 1996). Moreover, via
fluorescence in situ hybridization (FISH) technique, Yang and
his colleagues demonstrated the DNA synthesis process in the
neurons of the AD patients (Yang et al., 2001). In addition to
the above findings in AD patients, several in vitro studies
demonstrated that blockade of the G1–S transition using a
Cyclin D1 antisense or a dominant-negative mutant of Cdk4/6
could prevent the Aβ induced apoptosis (Copani et al., 2001;
Park et al., 1997). Thus, a substantial body of evidence has
associated the aberrant cell cycle re-entry in differentiated
neurons with neuronal apoptosis in AD.
In this study, we modeled neuronal loss in human AD
brains by exposing human forebrain neurons derived from iPS
cells to the insult of Aβ1–42 aggregates. Those neurons were
sensitive to Aβ toxicity and showed occurrence of CCEs
after Aβ1–42 treatment. Moreover, the aberrant cell cycle
re-entry and neuronal apoptosis were prevented by Cdk
inhibitors. Importantly, this finding was confirmed in a
commercially available forebrain neuronal population
(iCell® Neurons) derived from a different hiPS cell line.
The availability of large batches of iCell Neurons with consistent
quality enabled a small-molecule screen for compounds
that blocked the toxic effects of Aβ1–42 and demonstrated
the successful application of hiPS cells in drug screens for
neurodegenerative diseases.
Materials and methods
Chemicals and peptides
Roscovitine and Cdk4 inhibitor II were purchased from
Calbiochem (San Diego. CA, USA). 5-Bromo-2′-deoxyuridine
(BrdU), Olomoucine and GW8510 were from Sigma Aldrich (St.
Louis, MO, USA). Cdk2 inhibitor II was from Santa Cruz (Santa
Cruz, CA, USA). PD0332991 was from Axon Medchem (9713 GZ
Groningen, Netherlands). The recombinant Aβ1–42 peptides
were purchased from rPeptide (Athens, Georgia, USA). The
preparation of Aβ1–42 oligomers followed the previous
established protocol (Dahlgren et al., 2002) and western blot
analysis was performed to evaluate the formation of Aβ1–42
aggregates with Aβ antibody (6E10, Covance, Princeton, NJ,
USA) (Supplemental Fig. 1).
hiPS cell culture, forebrain neuron differentiation
and iCell Neurons culture
hiPS cell line UC C0406 iPS-C4 (hiPS-C4) was generated from
the urine cells of a healthy woman and maintained as
previously described (Zhou et al., 2011). Neural differenti-
ation of forebrain neurons from hiPS-C4 cells was performed
using a previously established protocol with some modifica-
tions (Chambers et al., 2009). Briefly, hiPS-C4 cells were
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washed by hiPS medium (80% DMEM/F12, 20% knockout
serum replacement, 1% non-essential amino acids, 2 mM
L-glutamine and 0.1 mM β-mercaptoethanol), and pre-
plated on gelatin for 1 h (hour) at 37 °C to remove MEFs.
The non-adherent hiPS cell clumps were cultured on petri
dishes in N2B27 medium (DMEM-F12/Neural Basal medium
1:1 with 1% N2, 2% B27, 1% non-essential amino acids, and
2 mM L-glutamine) supplemented with 10 μM Rock inhibitor
Y-27632 (Sigma Aldrich) for 8 h. Then the unattached
aggregates were collected and plated on dishes pre-coated
with 10 μg/mL poly-L-ornithine (Sigma Aldrich) and 10 μg/mL
laminin in N2B27 medium supplemented with 500 ng/mL
Noggin (PeproTech, Rocky Hill, NJ, USA) and 10 μM SB-431542
(Sigma Aldrich). After 12–14 days of culture, cells were
passaged with a cell scraper at a split ratio of 1:1. Those cells
(neural progenitor cells, NPCs) were cultured in N2B27medium
supplemented with bFGF (20 ng/mL), EGF (20 ng/mL) and
BDNF (PeproTech, 20 ng/mL), and passaged once every
4–5 days. For neural differentiation, NPCs were cultured in
N2B27 medium supplemented with BDNF (PeproTech,
20 ng/mL), GDNF (PeproTech, 20 ng/mL) and NT3 (PeproTech,
10 ng/mL) in 6 cm dishes at a density of 200,000 cells/cm2.
After 7 days of culture, cells were digested with accutase and
filtered with 40 μm cell strainer (BD Bioscience, San Jose,
California, USA) to collect single cells. In the final step of
differentiation, those differentiated cells were seeded on
plates pre-coated with 10 μg/mL poly-L-ornithine (Sigma
Aldrich) and 10 μg/mL laminin at a density of 50,000–
100,000 cells/cm2 for another 2–3 weeks of culture in N2B27
medium supplemented with BDNF (PeproTech, 20 ng/mL),
GDNF (PeproTech, 20 ng/mL) and NT3 (PeproTech, 10 ng/mL),
cAMP (N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophos-
phate, Sigma Aldrich, 10 μM), and 0.2 mM ascorbic acid
(STEMCELL Technologies, Vancouver, BC, Canada,). Differen-
tiated neurons were cultured in fresh N2B27 medium without
growth factors for 1–2 day(s) before Aβ toxicity assay. All
growth factors and reagents were from Life Technologies
(Carlsbad, CA, USA) unless noted otherwise.
iCell Neurons were purchased from Cellular Dynamics
International (Madison, WI, USA) and cultured according to
the manufacturer's instructions. Cells were used for Aβ
toxicity assay after 5–7 days post-thaw.
The human biological samples were sourced ethically and
all experiments involved in application of human samples
were approved by GlaxoSmithKline Human Biological Sample
User Committee.
Cell viability assay
Cell viability was measured by CellTiter-Glo Luminescent
Cell Viability Assay (Promega, Madison, WI, USA), according
to the manufacturer's instructions, and luminescence was
measured by the EnVision microplate reader (Perkin Elmer,
Waltham, MA, USA) or Glomax 96 microplate luminometer
(Promega).
Immunofluoresence and quantification
Cells were fixed with 4% paraformaldehyde (PFA) for 15 min
at room temperature. They were later permeabilized in 0.3%Triton-X100 for 20 min at room temperature, blocked with
3% normal donkey serum containing 0.1% Triton-X100 in
phosphate buffered saline (PBS) for 1 h at room tempera-
ture and stained with the primary antibodies at 4 °C
overnight. The following primary antibodies were used:
anti-vGAT, anti-vGLUT2 (Synaptic Systems, Goettingen,
Germany); anti-GABA, anti-MAP2 (Sigma Aldrich); anti-
SOX2, anti-Cdk2, anti-Cdk4 (Santa Cruz); anti-phos-Rb
(Ser795), anti-Cyclin D1 (Cell Signaling Technology, Essex,
Massachusetts, USA); anti-Nestin, anti-Tubulin, beta III
isoform, C-terminus, clone TU-20 (TuJ1, Millipore, Danvers,
MA, USA); anti-FOXG1 (Abcam, Cambridge, UK); anti-GFAP
(Dako, Carpinteria, CA, USA). For BrdU staining, cells were
incubated with 2 M HCl at room temperature for 30 min to
denature DNA, and incubated with primary antibodies at
4 °C overnight. After washing 3 times with PBS containing
0.1% Triton-X100, the cells were incubated with corre-
sponding Alexa Fluor 488 and Alexa Fluor 546 secondary
antibodies (all from Life Technologies) for 1 h at room
temperature, washed 3 times with PBS containing 0.1%
Triton-X100, incubated with 1 μg/mL 4′, 6-diamidino-2-
phenylindole (DAPI, Sigma Aldrich) for 10 min.
For TUNEL (terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labeling) staining, In Situ Cell Death
Detection Kit, Fluorescein (Roche, Basel, Switzerland) was
used. Briefly, cells were fixed with 4% PFA at room tem-
perature for 15 min and washed 3 times with PBS before
being stained with TUNEL reagent for 1 h in the absence of
light. For double staining of BrdU and TUNEL, cells were
incubated with 2 M HCl at room temperature for 30 min to
denature DNA, washed with PBS, incubated with anti-BrdU
(Santa Cruz) antibodies at 4 °C overnight, washed with PBS
and incubated with Alexa Fluor 594 goat anti-rat IgG (Life
Technologies) and TUNEL reagent for 1 h at room temper-
ature, and then washed cells 3 times with PBS.
For quantification, images were acquired from 6 to
8 non-overlapping fields on each coverslips using an LSM710
confocal microscope (Carl Zeiss, Oberkochen, Germany).
Cell numbers were counted in a double-blinded fashion.
Data used for analysis were collected from 3 independent
experiments with 2 to 3 replicates (corresponding to 2 to 3
coverslips) for every group in each experiment.Immunoblotting
The cells were lysed with RIPA buffer (Sigma Aldrich)
containing Halt™ Protease and Phosphatase Inhibitor Cock-
tail (Thermo Fisher, Philadelphia, PA, USA) for 20 min on
ice. The samples were incubated at 70 °C for 15 min in
Nupage sample buffer (Life Technologies) and proteins were
separated on Nupage 4%–12% Bris-Tris gels followed by
transfer to nitrocellulose membrane (Life Technologies) for
immunoblotting. The following primary antibodies were
used for detection: anti-Cdk2, anti-Cdk4 (Santa Cruz);
anti-Cyclin D1, anti-E2F1, anti-P21, anti-phos-Rb (Ser795)
(Cell Signaling Technology); anti-Cyclin A (Abcam); anti-Aβ
(6E10, Convance); anti-β-Actin-peroxidase (Sigma Aldrich).
All the secondary antibodies used for visualization were
either goat anti-mouse or goat anti-rabbit purchased from
Sigma Aldrich. Blots were developed with the SuperSignal
West Pico Chemiluminescent Substrate or SuperSignal West
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and visualized by the ImageQuant™ LAS 4000 biomolecular
imager (GE Healthcare Life Sciences, Pittsburgh, PA, USA).
Densitometry measurement of protein bands intensity was
carried out using ImageQuantTL software (GE Healthcare
Life Sciences).
RNA isolation, cDNA synthesis and real-time PCR
Cells were lysed using RLT Buffer and RNA was purified using
the RNeasy Mini Kit and the RNase-Free DNase Set (Qiagen,
Valencia, CA). For all samples, cDNA was generated using
PrimeScript® RT reagent Kit (Takara, Shiga, Japan). Quan-
titative real-time PCR was run on the LightCycler® 480 II
(Roche, Basel, Switzerland) using primers listed in Supple-
mental Table 1.
Electrophysiology
Patch clamp recordings were performed on hiPS-C4 cell-
derived neurons on Day 21. Neurons were perfused contin-
uously with buffer containing the following (in mM, all from
Sigma Aldrich): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES,
10 glucose (added before use) with pH 7.4. The thin-walled
borosilicate capillary glass (WPI, TW-150F-4) was pulled to
a resistance of 3–6 Mω using a horizontal pipette puller
(P-97, Sutter) and filled with intracellular solution
containing the following: (in mM, all from Sigma Aldrich):
140 KCl, 1 MgCl2, 2 CaCl2, 5 EDTA, 10 HEPES with pH 7.3.
Action potentials were recorded in the whole-cell current
clamp configuration. A current was injected to hold the
membrane potential at around −60 mV, and 10 ms of 200
pA depolarized current was injected until action potentials
were observed. Recordings were performed using an Axon
CNS Multiclamp 700B patch clamp amplifier and Digidata
1440A (Molecular Devices). Data were digitized at 10 kHz
and analyzed with Clampex 10.2, clampfit 10.2 Software
(Molecular Devices).
Neurite outgrowth assay
After treatment with Aβ1–42 aggregates and compounds,
the neurons were fixed with 4% PFA and then stained with
anti-TuJ1 antibody (Millipore) which specifically labels beta
III-tubulin in axons and dendrites. The Alexa Fluor 488
donkey anti-mouse IgG secondary antibodies (Life Technol-
ogies) and DAPI (Sigma Aldrich) were used before final
washing. The cells were scanned with Cellomics ArrayScan
VTI HCS Reader (Thermo Fisher) and analyzed with its
Neuronal profiling V4 algorithm. The average length per
neurite was used for assay readout.
shRNA construction, lentivirus generation and
infection
Human Cdk2 and Cdk4 small hairpins RNA (shRNA) were
prepared in pLVX-shRNA2 vector (Clontech, Mountain View,
CA, USA), based on the sequence of 5′-GGCCAGGAGTT
ACTTCTATGC-3′ and 5′-GCTGGAAATGCTGACCTTTAA-3′, re-
spectively. Lentivirus production and titer test were carriedout following the previously published protocol (Crittenden
et al., 2007). iCell Neurons were thawed and cultured for
3 days when virus at the multiplicity of infection (MOI) of 5
was added and incubated for 8 h before changing to fresh
medium. Cells were treated with 5 μM Aβ1–42 for 48 h after
5 days of infection. Then the number of GFP (+) cells and
total cells were counted with Acumen Explorer X3 (TTP
LabTech, Royston, UK) within 2 h post-fixation with 4% PFA.
All the virus related experiments were approved by the
Genetically Modified Organism (GMO) Management Commit-
tee of GlaxoSmithKline R&D China.
Flow cytometry analysis
iCell Neurons in culture were treated with TrypLE™ (Life
Technologies) to form a single cell suspension. Cells were
stained with LIVE/DEAD® Fixable Red Dead Cell Stain (Life
Technologies) prior to fixation by formaldehyde and perme-
abilization in fluorescence-activated cell sorting (FACS)
buffer containing 0.1% saponin. Cells were then stained
with a combination of mouse anti-human TuJ1-Alexa Fluor
488 and mouse anti-human Nestin Alexa Fluor 647 antibodies
or with the appropriately conjugated isotype controls (all
antibodies from BD Biosciences). Stained cells were analyzed
on an Accuri C6 flow cytometer. Flow cytometry data
analysis was performed using FCS Express (De Novo Soft-
ware) quantifying the percent TuJ1 (+)/Nestin (−) events
within the live cell population determined from the LIVE/
DEAD staining.
Aβ toxicity assay and compound screens
The iCell Neurons were thawed and cultured for 5 days at a
density of 8000 cells/well in 384-well plates before
compound addition and Aβ1–42 incubation. In the primary
screen, 50 nL of each compound in 10 mM stock from a GSK
proprietary tool compound set was transferred to 50 μL
media by the Echo Liquid Handling System (Labcyte,
Sunnyvale, CA, USA). After 2 h of incubation with com-
pounds containing media, 5 μM of Aβ1–42 or 0.2% DMSO
dissolved in fresh culture medium was added to the cells for
48 h treatment. Cell viability was measured by CellTiter-Glo
Luminescent Cell Viability Assay (Promega). The hits were
selected if the compounds increased the cell viability by at
least 3 times the standard deviation of the CellTiter-Glo
Luminescent measure over the mean cell viability of the cell
group treated by Aβ1–42 only.
Statistics
Dose–response curves were generated from XLfit (IDBS,
Burlington, MA, USA) using the dose–response onsite formula
as follows: fit=(A+(B/(1+((x/C)^D)))); inv=((((B/(y–A))–1)
^(1/D))*C); res=(y-fit). Other results were analyzed using the
GraphPad Prism 5 software (GraphPad Software, San Diego, CA,
USA) and were presented in the form of mean±SD. Unpaired
student's t-test or two-way ANOVA with Bonferroni post-tests
were used to evaluate the significance of differences between
means. In all cases, significance was noted at *Pb0.05,
**Pb0.01, ***Pb0.001.
Figure 1 Characterization of forebrain neurons derived from hiPS-C4 cells. A) Experimental scheme of neural differentiation from
hiPS-C4 cells. B, BDNF; G, GDNF; N, NT3; AA, ascorbic acid. Cells on Day 21 were ready for Aβ toxicity assay. B) Cells were labeled
with antibodies for Nestin (red), FOXG1 (red) and SOX2 (green) on Day 0. Scale bar, 20 μm. C) Cells were labeled with antibodies for
GFAP (red), TuJ1 (green), SOX2 (red) and MAP2 (green) on Day 21. DAPI (blue) was used for nuclei staining. Scale bar, 20 μm.
D) Analysis of cell percentages during different time points of differentiation. E) Real-time PCR results for cells on Day 21.
F) Spontaneous action potentials. G) Evoked action potentials. The values used for each column were mean±SD from 3 biological
replicates.
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Figure 2 Aβ1–42 induced neuronal apoptosis and aberrant cell cycle re-entry in hiPS-C4 cell-derived neurons. A) Cell viability was
measured at 24 h and 48 h. B) BrdU, red; TuJ1, green. C) The percentages of BrdU (+)/TuJ1 (+) cells were used for analysis. D) BrdU,
red; TUNEL, green. E) The percentages of BrdU (+)/TUNEL (−) cells and BrdU (+)/TUNEL (+) cells were used for analysis. F) Cyclin D1,
green; TuJ1, red. G) Cdk4, green; TuJ1, red. H) Cdk2, green; TuJ1, red. I) Phos-Rb, green; TuJ1, red. DAPI (blue) was used for nuclei
staining and scale bar=20 μm for all images. The values used for each column were mean±SD from 3 biological replicates and
***Pb0.001 was determined by unpaired t-test.
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Generation of forebrain neurons from hiPS-C4 cells
In neurodegenerative diseases, it is common that the
selective neuronal loss occurs in or initiates from restricted
regions of the brain. For example, progressive neuronal loss
has been observed in the cerebral cortex of AD patients.
Recently, human regional specific neurons were successfully
differentiated from ES and iPS cells (Bissonnette et al.,
2011; Hester et al., 2009; Zeng et al., 2010). NeuronalFigure 3 Cdk inhibitors prevented neuronal apoptosis in hiPS-C4 ce
compounds (Comp.) were generated with XLfit curve fitting softwa
D) The percentages of TUNEL (+) cells were used for analysis. E) The
used for each column were mean±SD from 3 biological replicates andifferentiation without exogenous morphogens will generate
the neuroepithelia cells that differentiate into cortical
progenitors and subsequently glutamatergic neurons and
GABAergic interneurons by default (Liu and Zhang, 2011). In
this study, we followed the previously established Dual-
SMAD inhibition protocol (Chambers et al., 2009) to generate
forebrain neurons in the absence of factors that confer the
regional specificity. After about two weeks of neural
induction with Noggin and SB431542 (Fig. 1A), we success-
fully obtained Nestin (+)/SOX2 (+) neural progenitor cells
(NPCs) from hiPS-C4 cells (Fig. 1B). Those NPCs havell-derived neurons. A–B) Full dose–response curves for indicated
re. C) TuJ1, red; TUNEL, green; DAPI, blue. Scale bar, 20 μm.
percentages of TuJ1 (+) cells were used for analysis. The values
d ***Pb0.001 was determined by unpaired t-test.
Figure 4 Prevention of Aβ1–42 induced cellular toxicity via inhibition of Cdks in iCell Neurons. A) iCell Neurons labeled with
antibodies for TuJ1 (green) on Day 1; MAP2 (green), GABA (red), vGAT (green) and vGLUT2 (red) on Day 14. Hoechst (blue) was used
for nuclei staining. Scale bar, 50 μm. B) Post-thaw purity of iCell Neurons as measured on Day 1 by flow cytometry for TuJ1 (neuronal
marker) and Nestin (neural stem/progenitor marker). C) Cell viability was analyzed with XLFit curve fitting software at different doses
and time points of Aβ1–42 treatment. D) Neurite was stained with TuJ1 antibodies (green) after 24 h Aβ1–42 treatment. E) Full dose–
response curves for indicated compounds (Comp.) were generated with XLfit curve fitting software. F) For neurite outgrowth assay,
cells were stained by anti-TuJ1 antibodies (green) after 36 h Aβ1–42 treatment. GW, GW8510. G) Average length per neurite was used
for analysis. H–I) Aβ1–42 induced neuronal death in cells after 5 days of infection by lentiviruses of shRNA2, shCdk2 and shCdk4. The
percentages of survived GFP (+) cells in different groups were obtained by the ratios of GFP (+) cells before and after Aβ1–42
treatment. The values used for each column were mean±SD from 3 biological replicates; *Pb0.05, **Pb0.01, ***Pb0.001 were
determined by unpaired t-test. Scale bar=20 μm for images in D), F) and H).
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221Cdk inhibition prevents Aβ induced toxicity in hiPS cell-derived neurons.predominantly a forebrain identity as they highly expressed
forebrain marker FOXG1 (Fig. 1B). We monitored the
expression of NPCs, glial cell and differentiated neuron
markers SOX2, GFAP, TuJ1 and MAP2 from Day 0 to Day 28.
TuJ1 and MAP2 expression increased over the course of
differentiation and reached the highest level on Day 21,
when the majority of NPCs became differentiated and lost
SOX2 expression. In contrast, the GFAP (+) glial cells started
to appear on Day 21 and further increased on Day 28
(Figs. 1C,D). In order to determine the expression file of
those differentiated neurons, real-time PCR analysis was
carried out on Day 21. Those cells expressed relative high
levels of markers for glutamatergic neurons (vGLUT1and
vGLUT2), GABAergic neurons (GAD65 and GAD67) and
cholinergic neurons (ChAT and VAChT), and with a low
percentage of cells expressing dopaminergic neuron marker
TH (Fig. 1E). Moreover, they also expressed high levels of
forebrain marker genes (FOXG1, OTX2) and with relatively
low levels of midbrain genes (PAX2) and hindbrain genes
(OLIG2 and HOXB6) on Day 21 (Fig. 1E). Electrophysiology
analysis demonstrated that spontaneous action potentials
(Fig. 1F) and evoked action potentials (Fig. 1G) were present
in those neurons on Day 21. We wanted to ask if those
functional forebrain neurons derived from hiPS-C4 cells
would be appropriate for modeling human AD in vitro, since
they include the susceptible neurons in human AD brains
such as glutamatergic neurons, GABAergic neurons and
cholinergic neurons.Induction of neuronal death and aberrant cell cycle
re-entry in hiPS-C4 cell-derived neurons by Aβ1–42
aggregates
The toxicity of Aβ1–42 to neurons has been demonstrated in
primary cortical and hippocampal neurons from rodent
brains, and differentiated neurons from neuronal cell lines
(Copani et al., 1999; Frasca et al., 2004; Troy et al., 2000;
Varvel et al., 2008). However, studies with Aβ1–42 toxicity
on hiPS cell-derived neurons are lacking. In this study,
different doses of Aβ1–42 were added to fully differentiated
hiPS-C4 cell-derived neurons, and cell viability was mea-
sured at 24 h and 48 h after treatment, respectively. Aβ1–
42 reduced neuronal survival in a dose- and time-dependent
manner, and with about 25% of neurons dying within 24 h
and 60% of neurons dying within 48 h after treatment at
5 μM Aβ1–42 (Fig. 2A).
A series of evidence for cell cycle re-entry has been found
in human AD brains, such as altered or inappropriate
expression of Cyclin D1, Cdk2/4, and Rb phospharylation in
AD neurons compared to age-matched controls (Busser et
al., 1998; Mosch et al., 2007; Ranganathan et al., 2001;
Smith et al., 1999). In mammalian cells, complexes of Cyclin
D1-Cdk4/6 and Cyclin E-Cdk2 regulate the G1–S phase
transition via phosphorylating Rb, which acts as a brake to
S phase entry. The activity of Cdks could be positively
regulated by increased expression of Cyclins and protein
shuttling of Cdks/Cyclins from cytoplasm to nucleus. To
analyze cell cycle re-entry in hiPS cell-derived neurons,
hiPS-C4 cell-derived neurons were treated with 5 μM Aβ1–
42 aggregates and expression pattern of G1 phase related
proteins were analyzed at different time points post-treatment. We found that Cyclin D1 was mainly detected in
the cytoplasm and gradually accumulated in the nuclear
area after 3 h to 8 h exposure to the Aβ1–42 (Fig. 2F).
Similar to Cyclin D1, Cdk4 and Cdk2 also showed trans-
locations from the cytoplasm to the nucleus after Aβ1–42
treatment (Figs. 2G,H), which was consistent with the
previous report in homocysteine treated rat cortical neurons
(Ye and Blain, 2010). Thus, in response to Aβ1–42 toxicity,
Cyclin D1, Cdk2 and Cdk4 appeared to translocate to the
nucleus, where they could form active complexes of Cyclin
D1–Cdk4 and Cyclin E–Cdk2 and phosphorylate their nuclear
substrates. Rb phosphorylation was highly detected in the
nuclear areas of the treated neurons, while it was barely
present in the controlled neurons (Fig. 2I). These observa-
tions indicated that those differentiated neurons had
re-entered cell cycle and reached the G1–S phase boundary
after Aβ1–42 treatment.
To further determine whether Aβ1–42 induced cell cycle
re-activation in hiPS-C4 cell-derived neurons, BrdU was used
to label newly synthesized DNA during S phase of the cell
cycle. We found a significant increase of BrdU (+)/TuJ1 (+)
neurons after Aβ1–42 treatment when compared with the
untreated groups (4.5%±3.2% versus 16.6%±4.6%) (Figs. 2B,
C). The results suggested that Aβ1–42 triggered the neurons
to re-entered cell cycle, and most of these cells (92.8%±
5.4%) traversing S phase were also undergoing apoptosis as
indicated by TUNEL signal (Figs. 2D,E).
Prevention of neuronal apoptosis in hiPS-C4
cell-derived neurons by Cdk inhibitors
Having demonstrated that the hiPS-C4 cell-derived neurons
with aberrant occurrence of CCEs would trigger neuronal
apoptosis, wewere interested in testing whether blocking Cdk
activity would protect these neurons. Two validated Cdk
inhibitors GW8510 and Cdk2 inhibitor II (Davis et al., 2001;
Sielecki et al., 2000) were found to protect hiPS-C4 cell-
derived neurons against Aβ1–42 toxicity in a dose-dependent
manner (Figs. 3A,B). TUNEL staining was performed to further
demonstrate reduction of programmed cell death induced by
Aβ1–42 for 24 h from 47.94%±4.26% to 33.41%±4.94% and
33.39%±4.02% by 1 μM GW8510 and 1 μM Cdk2 inhibitor II,
respectively, close to what was observed in the untreated
groups (22.95%±4.63%) (Figs. 3C,D). Meanwhile, 1 μMGW8510
and 1 μM Cdk2 inhibitor II prevented neuronal loss with
62.91%±5.47% and 59.56%±4.98% TuJ1 (+) cells, compared
with the Aβ1–42 treated groups (48.39%±4.37%) and
untreated control group (71.62%±4.84%) (Figs. 3C,E).
Confirmation of cellular toxicity and cell cycle
re-entry induced by Aβ1–42 in iCell Neurons
It is well known that hiPS cells have different differentiation
propensities among clones. There are also concerns that the
genetic variability of iPS cell clones contribute to phenotypic
differences of differentiated cells. Therefore, it is important
that we employed an independent hiPS cell clone to confirm
our findings in hiPS-C4 cell-derived neurons. iCell Neurons
are commercially available neurons derived from hiPS cells.
They were similar to our hiPS-C4 cell-derived neurons in that
they also represented forebrain identity andwere predominantly
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Supplemental Fig. 3). Importantly, iCell Neurons have one
distinct advantage for our study as they were highly pure
neuronswith 98.41% TuJ1 (+)/Nestin (−) cells characterized by
FACS (Fig. 4B) and few undifferentiated NPCs that might
interfere with cell imaging and biochemical characterization
of CCEs, were left in the population.
iCell Neurons were found to be similarly susceptible to Aβ
toxicity as hiPS-C4 cell-derived neurons. Aβ1–42 reduced
neuronal survival in a dose- and time-dependent manner, and
about 50% of iCell Neurons died within 24 h and 64% died
within 48 h after treatment by 5 μM Aβ1–42 (Fig. 4C). With a
population of pure neurons, neurite outgrowth could be
readily imaged and quantified. When treated with Aβ1–42 at
5 μM and 10 μM for 24 h, iCell Neurons reduced their average
neurite length to 71.48±1.29% and 38.77±3.65%, respective-
ly, normalized to the control group (100±3.8%) (Fig. 4D), a
finding consistent with the recent report in rat hippocampal
neurons (Nguyen et al., 2012). Moreover, GW8510 rescued the
neurite outgrowth reduction in a dose-dependent manner.
After 36 h incubation, Aβ1–42 reduced the average neurite
length of iCell Neurons to 25.40%±4.57% compared with the
control group (100%±5.54%) (Figs. 4F,G). GW8510 significantly
rescued the neurite length to 56.38±5.24%, 49.56±6.20%,
46.13±10.07% and 38.08%±7.36% at concentrations of 1 μM,
0.3 μM, 0.1 μM and 0.03 μM, respectively (Figs. 4F,G).
As GW8510 a pan Cdk inhibitor (inhibiting Cdk2/1/4) was
also effective in blocking Aβ induced toxicity in hiPS-C4
cell-derived neurons. We were curious about the role of
Cdk4, another key player of the G1–S transition in Aβ
induced cell cycle re-entry. Previous attempts in the
biochemical characterization of Cdk2 and Cdk4 in response
to Aβ toxicity in hiPS-C4 cell-derived neurons were compli-
cated due to the existence of identical proteins from
proliferating cells in that population. With a population of
pure neurons, we were able to detect expression changes of
cell cycle proteins after Aβ1–42 treatments. In our study,
we observed that the Cyclin D1 expression in iCell Neurons
increased from 3 h after Aβ1–42 treatment and the
increased level could be sustained for 20 h (Figs. 5A,C).
However, no significant increase in the Cdk4 expression was
seen (Figs. 5A,D). The phos-Rb expression was significantly
increased from 3 h to 8 h after Aβ1–42 treatment and
gradually decreased to the level of untreated group within
20 h (Figs. 5A,B). We found that Cdk2 expression increased
greatly by 3 h and 8 h treatment and the Cyclin A expression
increased from 8 h to 20 h after exposure to Aβ1–42
(Figs. 5A,E,F). These changes were expected to facilitate
the insulted neurons to transit from G1 phase to S phase,
which were consistent with our observation that E2F1
expression gradually increased from 3 h to 20 h after Aβ1–
42 treatment (Figs. 5A,H). Moreover, we discovered that the
Cdk inhibitor protein P21 increased by 3 h after treatment,
and then decreased significantly (Figs. 5A,G). In addition,Figure 5 Immunoblotting analysis of CCEs caused by Aβ1–42 in iCe
points (0 h, 3 h, 8 h and 20 h) after 5 μM Aβ1–42 treatment. anti-ph
anti-P21, anti-E2F1 and anti-Actin antibodies were used for immunob
were shown. The values used for each column were mean±SD from 3
group were determined by unpaired t-test. I–K) 1 μM GW8510 bloc
treatment. The values used for each column were mean±SD from 3 b
DMSO group were determined by two-way ANOVA with Bonferroni pwe observed that 1 μM GW8510 significantly reduced the
expression of phos-Rb (Figs. 5I,J) and E2F1 (Figs. 5I,K), which
were markers for cells actively progressing through cell
cycle G1 phase. This finding was consistent with the
observation reported in rat stroke model (Osuga et al.,
2000), and suggested that Cdk inhibitor GW8510 could
prevent the aberrant cell cycle re-entry caused by Aβ1–42
in iCell Neurons.
We selected 6 Cdk inhibitors with different specificities
to Cdk2 and Cdk4, as shown in Table 1 to test their
protective effects. Interestingly, two Cdk4 specific inhibi-
tors Cdk4 inhibitor II and PD0332991 failed to show
significant protective effects, while all other inhibitors
that inhibit Cdk2 protected neurons against Aβ1–42 toxicity
in a dose-dependent manner (Fig. 4E). This may indicate
that inhibition of Cdk2 rather than inhibition of Cdk4 could
rescue the neuronal death in iCell Neurons caused by Aβ1–
42 aggregates. To further confirm that it is inhibition of Cdk2
rather than Cdk4 was protective against Aβ1–42 toxicity, we
employed shRNAs against Cdk2 and Cdk4 in this toxic cellular
model. shCdk2 and shCdk4 could efficiently knockdown the
endogenous expression of Cdk2 (Supplemental Fig. 3A) and
Cdk4 in iCell Neurons (Supplemental Fig. 3B). We observed
that shCdk2 significantly increased the survival of GFP (+)
cells to 89.96±5.17% compared with the shRNA2 control group
(58.6±3.76%) (Figs. 4H,I). Intriguingly, cells transfected with
shCdk4 also increased the survival of GFP (+) cells, although
the specificity of shCdk4 was not ideal as some reduction of
Cdk2 was also observed. Moreover, it appears that shCdk2
protected neuronal deathmore efficiently than shCdk4. These
results were consistent with previous reports in Aβ treated rat
cortical neurons (Copani et al., 1999, 2001).
Screen for inhibitors of Aβ1–42 toxicity in iCell
Neurons
For drug screening, it is critical to have large quantities of
cells with consistent quality. iCell Neurons fulfilled these
criteria and allowed us to establish a high-throughput assay
using Aβ1–42 as the insult. Several hundred compounds from
a GSK proprietary compounds library were screened at 10 μM
for each compound. 19 compounds were selected as hits
based on the selection criteria outlined in the Materials and
methods (Fig. 6). Among the 19 hits, one of them was a Cdk2
inhibitor confirming the reliability and sensitivity of our
screening platform based on hiPS cell-derived neurons.
Discussion
AD is becoming more prevalent given that there is no cure and
our population is aging. A cellular model that could accurately
recapitulate AD pathology is critical for investigating the
pathogenic mechanisms and searching for treatments. Overll Neurons. A) Cell lystates were collected at a few different time
os-Rb (S795), anti-Cdk4, anti-Cyclin D1, anti-Cdk2, anti-Cyclin A,
lotting. B–H) Relative protein expression levels versus 0 h group
biological replicates; *Pb0.05, **Pb0.01, ***Pb0.001 versus 0 h
ked the increased phos-Rb and E2F1 after 3 h and 8 h Aβ1–42
iological replicates and **Pb0.01, ***Pb0.001 versus the value of
ost-tests for multiple comparisons.
Table 1 Commercial inhibitors of Cyclin-dependent
kinases
Name Supplier Catalog
no.
Inhibiting
target(s)
Roscovitine Calbiochem 557367 Cdk a1, Cdk2, Cdk5
Olomoucine Sigma Aldrich O0866 Cdk1, Cdk2, Cdk5
GW8510 Sigma Aldrich G7791 Cdk2, Cdk1, Cdk4
Cdk2 inhibitor II Santa Cruz sc-221409 Cdk2
Cdk4 inhibitor II Calbiochem 219477 Cdk4
PD0332991 Axon Medchem 1505 Cdk4, Cdk6
a Cdk: Cyclin-dependent kinase.
224 X. Xu et al.the past decades, scientists have used primary neurons from
rodent brains or immortalized neuronal cell lines to study AD
mechanisms and for drug screening. However, there are issues
and limitations for drug discovery studies with these models.
For example, there are important genetic and physiological
differences between human and animal brains, and primary
neurons from rodent do not reflect neuronal conditions in
human beings accurately. On the other hand, the immortal-
ized cell lines lose many features of human cells and their
intracellular regulations are significantly different from true
human neurons. The development of hiPS cell technology
holds great potential for drug discoveries for AD, as hiPS cells
with identical genetic makeup of patients' specific genetic
backgrounds can be readily established (Israel et al., 2012; Shi
et al., 2012; Yagi et al., 2011). Importantly, cortical neurons
derived from these hiPS cell lines carry important features of
AD pathology, such as increased generation of Aβ peptide.
However, it is disappointing that no neuronal loss from the
accumulation of Aβ peptide is observed and these iPS cell lines
could not be used for screening compounds against Aβ
toxicity. In our attempt to model AD, instead of using iPS
cells carrying genetic mutations implicated in the disease, we
used the neurons derived from healthy-subject iPS cells and
established a toxicity assay using Aβ1–42 aggregates. To ourFigure 6 Screen for inhibitors of Aβ1–42 toxicity in iCell Neuro
against Aβ1–42 toxicity showed that 19 compounds (blue dots) protknowledge, this is the first demonstration of the Aβ toxicity
assay using hiPS cell-derived neurons, which substantiates the
potential of the hiPS cells in high-throughput compound
screens.
One issue with using iPS cells is that random integration
of exogenous reprogramming genes might lead to clonal
heterogeneity and possible functional diversity. Therefore,
it is necessary to validate findings from one hiPS cell clone
with other independently derived hiPS cell clones. Another
potential issue is that it is usually challenging to generate a
large amount of highly purified cells for high-throughput
drug screening. Recently, iPS cell-derived derivatives have
become commercially available as cryopreserved assay-
ready cells (Prescott, 2011), relieving scientists from the
lengthy, laborious and complicated differentiation process.
General acceptance of these products in research and drug
discovery, however, requires detailed characterization and
validation studies (Chai et al., 2012; Whitemarsh et al.,
2012). In this study, we carried out side-by-side comparisons
of the iCell Neurons with our own iPS cell differentiated
neurons and confirmed that abnormal CCEs after Aβ1–42
treatment and rescuing the neuronal apoptosis by Cdk
inhibition could be observed in both cell populations,
consistent with the findings in H9 ES cell-derived neurons
(Supplemental Fig. 4). The availability of iCell Neurons in
large quantities should enable high-throughput screening
with a more physiologically relevant cellular model.
A series of studies have demonstrated that GABAergic
neurons were found to be affected in AD patients (Inaguma
et al., 1992; Mikkonen et al., 1999; Takahashi et al., 2010),
as well as cholinergic neurons and glutamatergic neurons
(Danysz et al., 2000; Muir et al., 1994; Selkoe, 2002).
However, some researchers believe that GABAergic neurons
were relatively resistant in AD due to their high expression of
calcium-binding proteins (CBPs) (Mattson and Magnus,
2006). In our cellular ADmodel, weemployed amixed neuronal
culture expressing GABAergic, glutamatergic, and cholinergic
neuron markers and we did not find that specific types of
neurons demonstrated significantly selective sensitivity tons. Scatter plot of all compounds with their protective effects
ected iCell Neurons against Aβ1–42 toxicity.
225Cdk inhibition prevents Aβ induced toxicity in hiPS cell-derived neurons.Aβ1–42 (Supplemental Fig. 5). It is possible that the neurons
used in these experiments are not mature enough to express
high levels of CBPs to afford the protection, compared with the
ones in AD patients. Moreover, different neuron culture
protocols, Aβ species, and treatment time may also lead to
the different neuronal susceptibility to toxic exposure (Krantic
et al., 2011; Pakaski et al., 1998). Further investigations may
be necessary to clarify the association between neuronal
mature extent and their susceptibility to Aβ toxic effects.
Cdk inhibitors have been widely tested in animal models of
central nervous system diseases including AD, PD, stroke and
traumatic brain injury (Hilton et al., 2008; Jorda et al., 2003;
Osuga et al., 2000). Though they have been demonstrated to
improve behavioral outcomes and increase neuronal survival
in those animal models, the lack of specificity of those Cdk
inhibitors may cause side effects and other issues. In previous
reports, Park et al. demonstrated that dominant negative
forms of Cdk4 and Cdk6, but not Cdk2 and Cdk3, prevented Aβ
induced neuronal death (Giovanni et al., 1999; Park et al.,
1997). While Copani et al. found that a dominant negative
mutant of Cdk2 also protected neurons against Aβ toxicity
(Copani et al., 1999, 2001). In our study, we found that both
shCdk2 and shCdk4 could decrease neuronal death caused by
Aβ, but shCdk2 were more effective than shCdk4. This
discrepancy might be caused by the different experimental
paradigms including different forms of Aβ aggregates,
different gene silencing methods and different neuronal cell
types used in those studies. It is still not clear from the current
study which factors from the aberrant CCEs trigger the
apoptosis pathways. The E2F1 related signaling pathways are
generally accepted to be involved in neuronal apoptosis. For
instance, E2F1 could induce caspase activation by directly
increasing intracellular Apaf-1 levels (Furukawa et al., 2002).
It also inhibits the NF-KB related survival signals and favors the
accumulation of ROS, which induce the occurrence of
apoptosis (Phillips et al., 1999). Furthermore, E2F1 also
might induce the expression of other apoptosis related
genes, such as Bcl2 (Eischen et al., 2001), Cdc2 (Konishi and
Bonni, 2003) and Bim (Biswas et al., 2005). In this study, we
found that Aβ1–42 treatment triggered DNA synthesis and
induced the increased expression of Cyclin D1, Cdk2 and Cyclin
A, though it should be noted that the cell cycle re-entry is only
one of the potential risk factors from the multitude of
activated signaling pathways in AD. The evidence suggests
that other activated mitogenic pathways also exist in a similar
manner. For example, MAPK/ERK1/2 signaling and PLC/IP3/
PKC/JNK signaling have been reported to be involved in the
cell cycle-reentry in AD researches (Frasca et al., 2004; Grant
et al., 2001; Lopez-Bergami and Ronai, 2008). The complexity
in AD mechanisms may account for our results demonstrating
that targeting the singlemolecule (Cdk2 inhibition) only partly
rescues and delays the neuronal apoptosis rather than
completely blocks neuronal death. Therefore, it will likely
be necessary to find additional signaling components in
addition of targeting Cdk2 for therapeutic interventions for
AD.
In summary, to establish a cellular model for AD, we used
Aβ1–42 aggregates as insults to induce the neuronal apoptosis
in the hiPS cell-derived neurons. We observed that abnormal
cell cycle re-entry occurred in hiPS cell-derived neurons after
Aβ1–42 treatment, and that a series of small-molecule Cdk
inhibitors and shRNAs against Cdk2 and Cdk4 could efficientlyblock the cellular toxicity elicited by Aβ1–42. Furthermore,
we performed a high-throughput drug screen and found some
potent small molecules which could efficiently prevent
neurons against Aβ toxic effects. Therefore, our study
provided an excellent example of how hiPS cells can be used
in disease modeling and high-throughput compound screening
for neurodegenerative diseases.
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